Evidence map›Paper›PMID 27570969›Full record

ArticlePloS one2016

A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models.

Natalia J Martinez, Ganesha Rai, Adam Yasgar, Wendy A Lea, Hongmao Sun, Yuhong Wang, Diane K Luci, Shyh-Ming Yang, Kana Nishihara, Shunichi Takeda and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Natalia J MartinezNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Ganesha RaiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Adam YasgarNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Wendy A LeaNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Hongmao SunNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Yuhong WangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Diane K LuciNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Shyh-Ming YangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Kana NishiharaNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Shunichi TakedaDepartment of Neurosurgery, John Hopkins University, Baltimore, MD 21231, United States of America.
Mohiuddin SagorDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo, Kyoto 606-8501, Japan.
Irina EarnshawDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo, Kyoto 606-8501, Japan.
Tetsuya OkadaDepartment of Biophysics, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwake, Sakyo, Kyoto 606-8502, Japan.
Kazutoshi MoriDepartment of Biophysics, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwake, Sakyo, Kyoto 606-8502, Japan.
Kelli WilsonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Gregory J RigginsDepartment of Neurosurgery, John Hopkins University, Baltimore, MD 21231, United States of America.
Menghang XiaNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Maurizio GrimaldiLaboratory of Neuropharmacology, Department of Biochemistry and Molecular Biology, Southern Research Institute, Birmingham, AL 35205, United States of America.
Ajit JadhavNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
David J MaloneyNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, United States of America.
National Center for Advancing Translational Sciences · USKyoto University · JPNational Institutes of Health · USSouthern Research Institute · US

Funding

A fully validated assay to identify activators of ERSR in human glioma cells: ideR03DA031669 · NIDA · SOUTHERN RESEARCH INSTITUTE · PI GRIMALDI, MAURIZIO · 2011 to 2012
$132k
NIDA NIH HHS R03 DA031669
6 · The paper itself

Abstract

The endoplasmic reticulum (ER) is involved in Ca2+ signaling and protein folding. ER Ca2+ depletion and accumulation of unfolded proteins activate the molecular chaperone GRP78 (glucose-regulated protein 78) which in turn triggers the ER stress response (ERSR) pathway aimed to restore ER homeostasis. Failure to adapt to stress, however, results in apoptosis. We and others have shown that malignant cells are more susceptible to ERSR-induced apoptosis than their normal counterparts, implicating the ERSR as a potential target for cancer therapeutics. Predicated on these findings, we developed an assay that uses a GRP78 biosensor to identify small molecule activators of ERSR in glioma cells. We performed a quantitative high-throughput screen (qHTS) against a collection of ~425,000 compounds and a comprehensive panel of orthogonal secondary assays was formulated for stringent compound validation. We identified novel activators of ERSR, including a compound with a 2,9-diazaspiro[5.5]undecane core, which depletes intracellular Ca2+ stores and induces apoptosis-mediated cell death in several cancer cell lines, including patient-derived and 3D cultures of glioma cells. This study demonstrates that our screening platform enables the identification and profiling of ERSR inducers with cytotoxic activity and advocates for characterization of these compound in in vivo models.

Indexed as

AlkanesAnimalsApoptosisBiological AssayBlotting, WesternCalciumCell Line, TumorEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressGliomaHeat-Shock ProteinsHT29 CellsHumansSignal TransductionAlkanesCalciumEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanundecane

Identifiers

PMID27570969
PMCPMC5003374
OpenAlexW2513828489

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.